The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Ampersand Capital and 1315 Capital have acquired Genoptix Inc. (clinical oncology diagnostics and informatics services) from Novartis AG for an undisclosed sum. The acquisition primarily includes Genoptix's commercial laboratory business; the firm's biopharma business was retained by Novartis and will operate as a new legal entity named Navigate Biopharma Services. Novartis originally purchased Genoptix for $440mm in 2011.

Update 10/2018

NeoGenomics has signed a definitive agreement to acquire Genoptix for $125mm in cash plus stock. See separate report.

+ Show All | – Hide All


Click a figure for comparable deals.

Equity Purchased As % 100%